Online inquiry

IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5645MR)

This product GTTS-WQ5645MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5645MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3116MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ15128MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ13485MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ13335MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ10921MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ9892MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ8394MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ13505MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW